Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenib
Agios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib.
Under the agreement, Agios will pay $25 million up front to Oscotec, a South Korean biotech, for the rights to develop and commercialize the drug, which targets immune thrombocytopenia.
The deal gives Agios control over the next generation inhibitor and positions the company to advance the candidate through clinical testing.
In a separate announcement, the Coalition for Epidemic Preparedness Innovations (CEPI) disclosed funding for three candidate Ebola vaccines, highlighting ongoing investment in pandemic preparedness.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that